Brazil’s antitrust regulator CADE is evaluating a request made by US-based Black River Asset Management to approve an acquisition of two local sugar mills, documents seen by Reuters on Friday showed.
The request sent to CADE indicates that Black River, controlled by US commodity trader Cargill, and Antonio Ruette Agroindustrial Ltda have agreed on terms for the mills’ sale and are awaiting the green light from the regulator.
Cargill and Regina Ruette, vice-president of Antonio Ruette Agroindustrial, confirmed in September that talks were going on for the Brazilian, family-owned company to sell the mills located in Paraiso and Ubarana, in the Sao Paulo state.
At that time, Cargill said it would only comment again when a possible deal had been reached, after due diligence. Regina Ruette also said in September the deal would value the company at around $180 million including debt.
Asked about the completion of the deal, Cargill said on Friday that Black River was an “independently managed subsidiary” and that questions should be sent to them. Black River declined to comment.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan